Skip to content

Naloxone

Opioid Antagonist — ALIMENTARY TRACT AND METABOLISM

Also known as: (-)-Naloxone, evzio, l-naloxone, naloxone HCl, naloxone hydrobromide, naloxone hydrochloride, naloxone hydrochloride dihydrate, naloxone hydrochloride hydrate

OfpEMA approvedFDA approvedATC A06AH04ATC N02AA53ATC N02AA55

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Naloxone is an ofp drug in the Opioid Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1971. Its mechanism of action is classified as Opioid Antagonists. DrugCentral lists 16 molecular targets, including Oprm1, OPRM1 and Oprk1. Recorded indications include Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate and Pain.

  • Approval status: ofp (first approved 1971 by the FDA).
  • Drug class: Opioid Antagonist.
  • Mechanism of action: Opioid Antagonists.
  • Molecular targets: Oprm1, OPRM1, Oprk1 and Oprm1 (16 listed in DrugCentral).
  • Indications: Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate, Pain and Poisoning by opiate analgesic drug and others.
  • ATC code: A06AH04 (Peripheral opioid receptor antagonists).
  • Molecular formula: C19H21NO4; molecular weight 327.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

  • Opiate-Induced Respiratory Depression
  • Opioid dependence
  • Overdose of opiate
  • Pain
  • Poisoning by opiate analgesic drug
  • Prevention of opioid abuse

Contraindications (57)

  • Acute abdominal pain
  • Adrenal cortical hypofunction
  • Alcohol intoxication
  • Alcohol withdrawal delirium
  • Asthenia
  • Benign intracranial hypertension
  • Benign prostatic hyperplasia
  • Bradycardia
  • Central nervous system depression
  • Chronic disease of respiratory system
  • Chronic hepatitis C
  • Chronic obstructive lung disease
  • Chronic type B viral hepatitis
  • Coma
  • Conduction disorder of the heart
  • Congenital long QT syndrome
  • Constipation
  • Cor pulmonale
  • Decreased respiratory function
  • Dehydration
  • Dependent drug abuse
  • Disease of liver
  • Disorder of biliary tract
  • Disorder of gallbladder
  • Drug-induced psychosis
  • Dysfunction of sphincter of Oddi
  • Exacerbation of asthma
  • Hypercapnia
  • Hypothyroidism
  • Hypoxia
  • + 27 more

Mechanism & targets

Mechanism of action (MoA)Opioid Antagonists
Established pharmacologic classOpioid Antagonist

Molecular targets (16)

TargetGeneActionActivity
Mu-type opioid receptorOprm1unknownKd 9.40
Mu-type opioid receptorOPRM1unknownKi 9.17
Kappa-type opioid receptorOprk1unknownKd 9.00
Mu-type opioid receptorOprm1antagonistKi 9.00
Opioid receptorOprd1|Oprm1|Oprk1|Sigmar1unknownKd 9.00
Mu-type opioid receptorOPRM1antagonistKi 8.81
Adenosine receptor A3ADORA3unknownIC50 8.80
Kappa-type opioid receptorOPRK1unknownKi 8.50
Kappa-type opioid receptorOPRK1antagonistKi 8.50
Mu-type opioid receptorOPRM1unknownIC50 8.30
Kappa-type opioid receptorOprk1antagonistIC50 8.30
C-C chemokine receptor type 5Ccr5unknownKd 7.98
Delta-type opioid receptorOprd1unknownKd 7.74
Delta-type opioid receptorOprd1unknownKd 7.30
Delta-type opioid receptorOPRD1antagonistKi 7.27
Cytochrome P450 2D6CYP2D6unknownIC50 5.70

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2017-11-09EMA—Mundipharma Corporation (Ireland) Limited
1971-04-13FDA—ADAPT

ATC classification

ATC codeTherapeutic hierarchy
A06AH04ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Peripheral opioid receptor antagonists
N02AA53NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Natural opium alkaloids
N02AA55NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Natural opium alkaloids
N02AD51NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Benzomorphan derivatives
N02AX51NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Other opioids
V03AB15VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Antidotes

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Toxicity to various agents847.4
Overdose476.5
Drug withdrawal syndrome362.0
Drug withdrawal syndrome neonatal333.6
Respiratory depression300.4
Unresponsive to stimuli245.9
Miosis202.6
Drug abuse185.1
Pulmonary oedema137.3
Non-cardiogenic pulmonary oedema136.0
Exposure during pregnancy132.0
Depressed level of consciousness125.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Naloxone is on its molecule page.

Molecular formulaC19H21NO4
Molecular weight327.38 g/mol
CAS number465-65-6
InChIKeyUZHSEJADLWPNLE-GRGSLBFTSA-N
PubChem CID5284596
OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Naloxone used for?

DrugCentral lists the following indications for Naloxone: Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate, Pain, Poisoning by opiate analgesic drug and Prevention of opioid abuse.

How does Naloxone work?

Naloxone is classified as Opioid Antagonists; its molecular targets in DrugCentral include Oprm1, OPRM1, Oprk1 and Oprm1 (antagonist).

When was Naloxone first approved?

Naloxone was first approved by the FDA in 1971.

What drug class does Naloxone belong to?

Naloxone is in the Opioid Antagonist class.

What is the chemical formula of Naloxone?

Naloxone has the molecular formula C19H21NO4 and a molecular weight of 327.38 g/mol.

Browse: all drugs starting with N · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1971-04-13
AgencyFDA
Targets16
Indications6
FormulaC19H21NO4
DrugCentral ID1878
Interactive profile